Monday, April 9, 2012


Our breast unit was one of four UK Hospitals where patients were recruited into the phase 3 NeoALTTO Clinical Trial. The Trial was conducted in 23 countries around the world and is registered with, NCT00553358. Results of this trial of dual inhibition of Her 2 in the neoadjuvant ( treatment prior to surgery) setting have been published in the Lancet .  The results show that the rate of pathological complete response (no tumour found at surgery) was significantly higher in the group given lapatinib (Tyverb) and trastuzumab (Herceptin) than trastuzumab or lapatinib alone.